Ac-DEVD-CHO is a selective Caspase-3 inhibitor (Ki: 230 pM).

The addition of Ac-DEVD-CHO significantly prevents SLNT-induced apoptosis (from 32.91% decreases to 15.88% while NC and Ac-DEVD-CHO groups are 6.45%, 7.77%, respectively) [2]. Ac-DEVD-CHO (10 μmol/L) partially blocks the effect of SIN-induced apoptosis and reduces the number of apoptotic nuclei. These effects of SIN are blocked by the caspase-3 inhibitor Ac-DEVD-CHO. Camptothecin (4 μM), a positive control, increases caspase-3 activity, which is also blocked by Ac-DEVD-CHO [3].

Compare with model group, in CI group, the concentrations of serum BUN are decreased significantly at all time points after operation and those of Cr are decreased significantly at 6 hours, then restored to those of the sham group at 12 hours and 24 hours; the concentrations of serum TNF-α, IL-6 are decreased and those of IL-10 are elevated significantly at all time points. [TNF-α (μg/L) 6 hours: 436.2±64.2 vs. 653.6±8.9, 12 hours: 233.4±85.4 vs. 579.7±137.1, 24 hours: 151.0±90.3 vs. 551.0±119.8, IL-6 (μg/L) 6 hours: 1033.2±345.8 vs. 1 595.3±159.4, 12 hours: 366.3±68.3 vs. 1 330.7±249.8, 24 hours: 241.2±208.4 vs. 815.3±572.7, IL-10 (μg/L) 6 hours: 33.6±10.4 vs. 26.6±4.5, 12 hours: 37.2±5.0 vs. 24.5±4.3, 24 hours: 38.3±5.5 vs. 18.2±1.6, all P<0.05] [4].

169332-60-9

C20H30N4O11

502.47

Ac-DEVD-CHO

H2O:50 mg/mL (99.51 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years